SVRA 📈 Savara - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8051111016
SVRA: Respiratory, Pulmonary, Proteinosis, Autoimmune, Inhaled, Treatment
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania. Web URL: https://www.savarapharma.com
Additional Sources for SVRA Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SVRA Stock Overview
| Market Cap in USD | 638m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2017-06-01 |
SVRA Stock Ratings
| Growth 5y | -0.77% |
| Fundamental | -59.3% |
| Dividend | - |
| Rel. Strength Industry | -1976 |
| Analysts | 4.29/5 |
| Fair Price Momentum | 2.36 USD |
| Fair Price DCF | - |
SVRA Dividends
No Dividends PaidSVRA Growth Ratios
| Growth Correlation 3m | -68.4% |
| Growth Correlation 12m | -79.3% |
| Growth Correlation 5y | 58.4% |
| CAGR 5y | -2.42% |
| CAGR/Mean DD 5y | -0.06 |
| Sharpe Ratio 12m | -0.36 |
| Alpha | -56.73 |
| Beta | 1.03 |
| Volatility | 56.07% |
| Current Volume | 713k |
| Average Volume 20d | 1224.5k |
What is the price of SVRA stocks?
As of January 03, 2025, the stock is trading at USD 3.07 with a total of 712,967 shares traded.
Over the past week, the price has changed by -6.40%, over one month by -7.11%, over three months by -21.28% and over the past year by -29.75%.
As of January 03, 2025, the stock is trading at USD 3.07 with a total of 712,967 shares traded.
Over the past week, the price has changed by -6.40%, over one month by -7.11%, over three months by -21.28% and over the past year by -29.75%.
Is Savara a good stock to buy?
No, based on ValueRay Fundamental Analyses, Savara (NASDAQ:SVRA) is currently (January 2025) a stock to sell. It has a ValueRay Fundamental Rating of -59.26 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SVRA as of January 2025 is 2.36. This means that SVRA is currently overvalued and has a potential downside of -23.13%.
No, based on ValueRay Fundamental Analyses, Savara (NASDAQ:SVRA) is currently (January 2025) a stock to sell. It has a ValueRay Fundamental Rating of -59.26 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SVRA as of January 2025 is 2.36. This means that SVRA is currently overvalued and has a potential downside of -23.13%.
Is SVRA a buy, sell or hold?
Savara has received a consensus analysts rating of 4.29. Therefor, it is recommend to buy SVRA.
Savara has received a consensus analysts rating of 4.29. Therefor, it is recommend to buy SVRA.
- Strong Buy: 3
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for SVRA stock price target?
According to ValueRays Forecast Model, SVRA Savara will be worth about 2.6 in January 2026. The stock is currently trading at 3.07. This means that the stock has a potential downside of -14.66%.
According to ValueRays Forecast Model, SVRA Savara will be worth about 2.6 in January 2026. The stock is currently trading at 3.07. This means that the stock has a potential downside of -14.66%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 9.8 | 218.9% |
| Analysts Target Price | 5.5 | 79.2% |
| ValueRay Target Price | 2.6 | -14.7% |